A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.

ABSTRACT:

Lessons learned

Oral targeted agents are desirable for treatment of Kaposi sarcoma (KS); however, in patients with HIV, drug-drug interactions must be considered. In this study to treat KS, sorafenib was poorly tolerated at doses less than those approved by the U.S. Food and Drug Administration for hepatocellular carcinoma and other cancers, and showed only modest activity.Sorafenib's metabolism occurs via the CYP3A4 pathway, which is inhibited by ritonavir, a commonly used antiretroviral agent used by most patients in this study. Strong CYP3A4 inhibition by ritonavir may contribute to the observed sorafenib toxicity.Alternate antiretroviral agents without predicted interactions are preferred for co-administration in patients with HIV and cancers for which sorafenib is indicated.

SUBMITTER: Uldrick TS 

PROVIDER: S-EPMC5423501 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature